Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ACUS ACUSPHERE INC

No earlier versions found for this Subject.

Return to ACUS ACUSPHERE INC

Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microsphere technology.

This company has been beat up and is a turn around candidate with great potential in my opinion.

This thread is for discussion of the products, outlook for partnerships, and the ability for the PPS to increase.
I am long and enthusiastic about the opportunities with this company.

Acusphere Inc (ACUS ) said final late-stage trial data showed that its echocardiography imaging agent Imagify Perfusion Stress Echo, which is used to assess coronary heart disease, is well-tolerated. {Discussions for partnership ongoing}

Acusphere to Develop Potential Abraxane(R) Bioequivalent

Acusphere, Inc. (NASDAQ: ACUS - News) announced today that its product candidate AI-850 has a comparable pharmocokinetic profile to the breast cancer drug Abraxane® based upon human data available in publications on each drug. AI-850 is Acusphere’s patented formulation of paclitaxel, the active ingredient in Abraxane. {Partnership with Major Parma probable } Fast tracked!